Treatment Experiences, Information Needs, Pain and Quality of Life in Men with Metastatic Castrate-resistant Prostate Cancer: Results from the EXTREQOL Study

Jenkins, Valerie; Solis-Trapala, Ivonne; Payne, Heather; Mason, Malcolm David; Fallowfield, Lesley; May, Shirley; Matthews, Lucy; Catt, Susan

doi:10.1016/j.clon.2018.11.001

Cited by 14 publications

(17 citation statements)

References 30 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who managed to have a pain management discussion were in the main satisfied; however, some attributed their pain to their older age, or to conditions other than cancer, for example arthritis, or an activity like gardening. Evidence from the Brief Pain Inventory data for the whole EXTREQOL study sample showed only 39% (22/57) of those with moderate/severe pain experienced ≥ 70% pain relief from their analgesia, and these proportions dropped to 37.5% (15/40) and 36.5% (15/41) at 3 & 6 months follow‐up respectively (Jenkins et al, ). The overall picture from EXTREQOL and other studies is one of less than optimal pain management in this group of men.…”

Section: Discussionmentioning

confidence: 99%

Patients’ and partners’ views of care and treatment provided for metastatic castrate‐resistant prostate cancer in the UK

et al. 2019

View full text Add to dashboard Cite

Objective Documentations of the experiences of patients with advanced prostate cancer and their partners are sparse. Views of care and treatment received for metastatic castrate‐resistant prostate cancer (mCRPC) are presented here. Methods Structured interviews conducted within 14 days of a systemic therapy for mCRPC starting and 3 months later explored the following: treatment decisions, information provision, perceived benefits and harms of treatment, and effects of these on patients’ and partners’ lives. Results Thirty‐seven patients and 33 partners recruited from UK cancer centres participated. The majority of patients (46%) reported pain was their worst symptom and many wanted to discuss its management (baseline‐50%; 3 months‐33%). Patients and partners believed treatment would delay progression (>75%), improve wellbeing (33%), alleviate pain (≈12%) and extend life (15% patients, 36% partners). At 3 months, most men (42%) said fatigue was the worst treatment‐related side effect (SE), 27% experienced unexpected SEs and 54% needed help with SEs. Most patients received SE information (85% written; 75% verbally); many additionally searched the Internet (33% patients; 55% partners). Only 54% of patients said nurse support was accessible. Conclusion Pain and other symptom management are not optimal. Increased specialist nurse provision and earlier palliative care links are needed. Dedicated clinics may be justified.

show abstract

Section: Discussionmentioning

confidence: 99%

Patients’ and partners’ views of care and treatment provided for metastatic castrate‐resistant prostate cancer in the UK

et al. 2019

View full text Add to dashboard Cite

show abstract

“…When men are facing life-prolonging treatments, it is, therefore, important to consider and discuss both the benefits and possible harmful effects of the treatments when communicating with the patient (Winkler et al, 2012;Haun et al, 2017). In a recent study, men with mCRPC reported lacking enough information on how the treatment might affect them and their life situation and also on how to access supportive resources (Jenkins et al, 2019). A majority of the men in the present study received chemotherapy as their first life-prolonging treatment but all types of treatments the men received require regular follow-ups and treatment evaluation, something that is commonly handled by contact nurses at the oncology clinics in the Swedish context.…”

Section: Discussionmentioning

confidence: 99%

“…A review of the needs and experiences of men with PC ranging from localized disease to an advanced, palliative phase highlights the men's need for information about treatment options as well as the expected severity and duration of side effects (King et al, 2015). Still, it has been shown that men with mCRPC lack enough information about the treatments and their possible impact of them on their life (Jenkins et al, 2019). Further, QoL has been shown to be more important to men with mCRPC than extending life expectancy with the risk of experiencing debilitating treatment complications (Jones et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Facing life-prolonging treatment: The perspectives of men with advanced metastatic prostate cancer – An interview study

Doveson

Holm

Axelsson

et al. 2020

European Journal of Oncology Nursing

View full text Add to dashboard Cite

Several life-prolonging treatment options have recently become available for metastatic castrationresistant prostate cancer. However, research regarding patient experiences while undergoing these treatments is scarce. The aim was to explore the perspectives of men when facing life-prolonging treatment of metastatic castration-resistant prostate cancer. Method: Qualitative interviews were conducted with 16 men as they were starting, undergoing or had completed their first life-prolonging treatment. Interpretive description was used for analysis. Results: The results illuminate the complexity of facing life-prolonging treatment, with interlaced dimensions beyond just the outcome, and where the men described other dimensions of their lives in relation to the treatment. The results are presented as 4 themes; Considering treatment when the remainder of life is at stake, Preparing for the life-prolonging treatment after deciding to go through with it, Considering the prospect of the life-prolonging treatment not being successful and Reflecting on death and dying in the light of a life-limiting illness. Conclusions: The quality and content of the remainder of life are central for men when facing life-prolonging treatment of metastatic castration-resistant prostate cancer. This is important when weighing desired treatment outcomes against side effects, and when reflecting upon whether going through with treatment would be worth it or not. The results illuminate the importance of encouraging men at this stage to express expectations, hopes and fears regarding the treatment and the future when considering life-prolonging treatments. Nurses working with these patients are important in the decision-making process and in evaluating treatments, to detect needs for interventions.

show abstract

“…Besides being a surrogate endpoint for mortality, metastatic disease is an important clinical outcome in its own right due to the adverse impact on quality of life of the disease and its treatments, whether the metastases are present at diagnosis or occur later through progression. 8,9 ERSPC analyzed rates of total metastatic disease (metastases at diagnosis plus metastatic progression) by arm in a subset of its centers and showed a reduction similar to, but slightly larger than, the reduction in prostate cancer mortality in the trial. 10 The CAP trial reported only on metastatic disease at diagnosis (M1), which was grouped together with N1 and T4 disease, and showed a statistically significant reduction in T4, N1, or M1 disease in the screening arm versus the control arm.…”

Section: Introductionmentioning

confidence: 99%

“…[2][3][4][5] One of these trials, the European Randomized Study of Screening for Prostate Cancer (ERSPC), found a significant reduction in prostate cancer mortality. 8,9 ERSPC analyzed rates of total metastatic disease (metastases at diagnosis plus metastatic progression) by arm in a subset of its centers and showed a reduction similar to, but slightly larger than, the reduction in prostate cancer mortality in the trial. [3][4][5][6][7] An important additional goal of PSA screening is reducing the rate of metastatic prostate cancer, and this was a secondary endpoint of the screening trials.…”

Section: Introductionmentioning

confidence: 99%

Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Pinsky

Daugherty

Hoover

et al. 2019

Cancer

View full text Add to dashboard Cite

BACKGROUND:The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial assessed the effect of screening with prostate-specific antigen and a digital rectal examination on prostate cancer mortality. Another endpoint of interest was the burden of total metastatic disease. METHODS: All men in PLCO were assessed for metastatic prostate cancer at diagnosis; men with clinical stage I/II disease were assessed for metastatic progression. The rate of total metastatic disease was defined as metastases found either at diagnosis or through progression divided by person-years (PYs) of follow-up for all men in the trial. Metastatic progression rates were computed among men with clinical stage I/II prostate cancer. Survival among men with metastases at diagnosis was compared with survival among men with metastatic progression. RESULTS: Among 38,340 men in the intervention arm and 38,343 men in the control arm in PLCO, there were 4974 and 4699 prostate cancer cases, respectively. The rates of total metastatic disease were 4.72 and 4.83 per 10,000 PYs in the intervention and control arms, respectively (rate ratio, 0.98; 95% CI, 0.81-1.18). The rates of metastatic progression among men with clinical stage I/II prostate cancer were 43.7 and 50.5 per 10,000 PYs in the intervention and control arms, respectively (P = .30). Prostate cancer-specific 5-and 10-year survival rates were significantly worse for men with metastatic progression (24% and 19%, respectively) than men with metastases at diagnosis (40% and 26%, respectively). CONCLUSIONS: Rates of total metastatic disease and metastatic progression were similar across arms in PLCO. Survival was worse for men with metastatic progression in comparison with those with metastatic disease at diagnosis.

show abstract

Treatment Experiences, Information Needs, Pain and Quality of Life in Men with Metastatic Castrate-resistant Prostate Cancer: Results from the EXTREQOL Study

Cited by 14 publications

References 30 publications

Patients’ and partners’ views of care and treatment provided for metastatic castrate‐resistant prostate cancer in the UK

Patients’ and partners’ views of care and treatment provided for metastatic castrate‐resistant prostate cancer in the UK

Facing life-prolonging treatment: The perspectives of men with advanced metastatic prostate cancer – An interview study

Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Contact Info

Product

Resources

About